Talus Bioscience

Executive Summary

Talus Bioscience is a Seattle-based pre-clinical biotechnology company founded in 2021 that specializes in decoding the regulome—the dynamic system controlling gene expression—to identify novel drug targets and develop first-in-class therapies. By integrating AI/ML, functional proteomics, and high-throughput live-cell screening, the company aims to measure and modulate gene regulators, unlocking new opportunities in complex diseases. Despite being in early stages with no disclosed funding rounds or valuation, Talus's platform addresses a critical gap in understanding non-coding regulatory elements and transcription factor networks, which could lead to breakthroughs in oncology, immunology, and rare diseases. The company's approach is differentiated from traditional genomic or proteomic platforms by its focus on the dynamic regulation of gene activity rather than static sequences or protein abundance, potentially offering more druggable targets. However, its pre-clinical stage and lack of publicly disclosed partnerships or funding means significant execution risk remains. The executive team's expertise in AI and functional genomics supports the scientific premise, but validation in animal models and eventual clinical translation are necessary milestones.

Upcoming Catalysts (preview)

• 2026Series A Financing Round70% success
• 2026First In Vivo Proof-of-Concept Data for Lead Program40% success
• 2027Strategic Partnership with Pharma for Platform Access50% success